Pomanda estimates the enterprise value of KIDNEY CANCER CARE LIMITED at £145.2k based on a Turnover of £289.9k and 0.5x industry multiple (adjusted for size and gross margin).
kidney cancer care limitedEstimated Valuation
£316.1k
Pomanda estimates the enterprise value of KIDNEY CANCER CARE LIMITED at £316.1k based on an EBITDA of £81.9k and a 3.86x industry multiple (adjusted for size and gross margin).
kidney cancer care limitedEstimated Valuation
£358.8k
Pomanda estimates the enterprise value of KIDNEY CANCER CARE LIMITED at £358.8k based on Net Assets of £152.8k and 2.35x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Kidney Cancer Care LimitedOverview
Kidney Cancer Care Limited is a live company located in guildford, GU4 7HN with a Companies House number of 05937304. It operates in the other human health activities sector, SIC Code 86900. Founded in September 2006, it's largest shareholder is
unknown.
Kidney Cancer Care Limited is a established,
micro sized company, Pomanda has estimated its turnover at
£289.9k with
declining
growth in recent years.
Pomanda's financial health check has awarded Kidney Cancer Care Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 4 areas for improvement. Company Health Check FAQs
Health Rating5out of 5
6 Strong
1 Regular
4 Weak
Size
annual sales of £289.9k, make it smaller than the average company (£750.6k)
£289.9k - Kidney Cancer Care Limited
£750.6k - Industry AVG
Growth
3 year (CAGR) sales growth of -5%, show it is growing at a slower rate (8%)
-5% - Kidney Cancer Care Limited
8% - Industry AVG
Production
with a gross margin of 38.9%, this company has a comparable cost of product (38.9%)
38.9% - Kidney Cancer Care Limited
38.9% - Industry AVG
Profitability
an operating margin of 28.2% make it more profitable than the average company (5.5%)
28.2% - Kidney Cancer Care Limited
5.5% - Industry AVG
Employees
with 5 employees, this is below the industry average (18)
5 - Kidney Cancer Care Limited
18 - Industry AVG
Pay Structure
on an average salary of £21.9k, the company has a lower pay structure (£27.6k)
£21.9k - Kidney Cancer Care Limited
£27.6k - Industry AVG
Efficiency
resulting in sales per employee of £58k, this is more efficient (£49.2k)
£58k - Kidney Cancer Care Limited
£49.2k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Kidney Cancer Care Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 1 days, this is quicker than average (16 days)
1 days - Kidney Cancer Care Limited
16 days - Industry AVG
Stock Days
it holds stock equivalent to 6 days, this is less than average (15 days)
6 days - Kidney Cancer Care Limited
15 days - Industry AVG
Cash Balance
has cash to cover current liabilities
for 490 weeks, this is more cash available to meet short term requirements (111 weeks)
490 weeks - Kidney Cancer Care Limited
111 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 10%, this is a lower level of debt than the average (24%)
10% - Kidney Cancer Care Limited
24% - Industry AVG
KIDNEY CANCER CARE LIMITED financials
EXPORT
Kidney Cancer Care Limited's latest turnover from September 2024 is £289.9 thousand and the company has net assets of £152.8 thousand. According to their latest financial statements, Kidney Cancer Care Limited has 5 employees and maintains cash reserves of £160.6 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Sep 2024
Sep 2023
Sep 2022
Sep 2021
Sep 2020
Sep 2019
Sep 2018
Sep 2017
Sep 2016
Sep 2015
Sep 2014
Sep 2013
Sep 2012
Sep 2011
Sep 2010
Sep 2009
Turnover
289,934
254,102
396,175
339,710
297,702
326,276
374,210
334,572
357,859
309,307
195,612
224,356
168,714
271,865
176,040
140,262
Other Income Or Grants
Cost Of Sales
177,144
156,743
248,307
224,874
191,129
208,700
242,349
207,020
220,980
193,493
121,846
137,046
97,773
156,907
98,787
Gross Profit
112,790
97,359
147,868
114,836
106,573
117,576
131,861
127,552
136,879
115,814
73,766
87,310
70,941
114,958
77,253
Admin Expenses
30,916
173,313
153,104
41,965
146,942
228,114
192,640
130,293
45,674
64,155
19,379
105,211
142,562
89,145
70,890
-5,654
Operating Profit
81,874
-75,954
-5,236
72,871
-40,369
-110,538
-60,779
-2,741
91,205
51,659
54,387
-17,901
-71,621
25,813
6,363
5,654
Interest Payable
Interest Receivable
Pre-Tax Profit
66,132
-69,119
-1,195
59,159
-40,216
-108,847
-58,567
-1,961
73,360
41,567
43,078
-17,837
-71,456
19,339
4,812
4,172
Tax
Profit After Tax
66,132
-69,119
-1,195
59,159
-40,216
-108,847
-58,567
-1,961
73,360
41,567
43,078
-17,837
-71,456
19,339
4,812
4,172
Dividends Paid
Retained Profit
66,132
-69,119
-1,195
59,159
-40,216
-108,847
-58,567
-1,961
73,360
41,567
43,078
-17,837
-71,456
19,339
4,812
4,172
Employee Costs
109,735
199,609
173,978
142,218
108,750
114,841
69,997
27,332
20,429
190,895
107,484
128,441
105,369
167,132
102,092
Number Of Employees
5
7
8
6
5
5
3
2
1
9
5
6
5
8
5
EBITDA*
81,874
-75,173
-4,755
73,352
-39,571
-109,762
-60,140
-2,209
91,687
52,032
54,573
-16,989
-70,669
26,542
7,252
5,973
* Earnings Before Interest, Tax, Depreciation and Amortisation
Sep 2024
Sep 2023
Sep 2022
Sep 2021
Sep 2020
Sep 2019
Sep 2018
Sep 2017
Sep 2016
Sep 2015
Sep 2014
Sep 2013
Sep 2012
Sep 2011
Sep 2010
Sep 2009
Tangible Assets
781
200
282
961
757
733
767
267
640
80
992
1,640
819
320
Intangible Assets
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets
781
200
282
961
757
733
767
267
640
80
992
1,640
819
320
Stock & work in progress
3,164
4,265
2,808
3,395
3,529
4,978
6,573
1,439
868
200
569
643
1,000
3,480
4,320
3,768
Trade Debtors
1,463
969
7,626
Group Debtors
Misc Debtors
6,003
15,738
8,486
21,556
22,390
19,829
3,270
21,335
8,107
7,999
5,511
16,274
20,073
40,787
4,717
11,348
Cash
160,631
91,454
168,925
190,280
138,503
167,320
283,518
306,278
317,500
78,691
41,156
15,695
9,944
56,221
72,213
56,014
misc current assets
total current assets
169,798
111,457
180,219
215,231
164,422
192,127
294,824
330,021
326,475
86,890
54,862
32,612
31,017
100,488
81,250
71,130
total assets
169,798
111,457
181,000
215,431
164,704
193,088
295,581
330,754
327,242
87,157
55,502
32,692
32,009
102,128
82,069
71,450
Bank overdraft
Bank loan
Trade Creditors
928
5,554
2,205
4,550
8,636
6,143
26,732
14,748
13,300
16,241
13,965
32,128
16,225
13,724
14,314
Group/Directors Accounts
other short term finances
hp & lease commitments
other current liabilities
16,111
19,276
23,049
53,940
58,286
48,947
22,004
10,594
6,569
39,636
3,871
3,476
3,359
4,522
3,212
11,719
total current liabilities
17,039
24,830
25,254
58,490
66,922
55,090
48,736
25,342
19,869
55,877
17,836
35,604
19,584
18,246
17,526
11,719
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
2,500
total long term liabilities
2,500
total liabilities
17,039
24,830
25,254
58,490
66,922
55,090
48,736
25,342
19,869
55,877
17,836
38,104
19,584
18,246
17,526
11,719
net assets
152,759
86,627
155,746
156,941
97,782
137,998
246,845
305,412
307,373
31,280
37,666
-5,412
12,425
83,882
64,543
59,731
total shareholders funds
152,759
86,627
155,746
156,941
97,782
137,998
246,845
305,412
307,373
31,280
37,666
-5,412
12,425
83,882
64,543
59,731
Sep 2024
Sep 2023
Sep 2022
Sep 2021
Sep 2020
Sep 2019
Sep 2018
Sep 2017
Sep 2016
Sep 2015
Sep 2014
Sep 2013
Sep 2012
Sep 2011
Sep 2010
Sep 2009
Operating Activities
Operating Profit
81,874
-75,954
-5,236
72,871
-40,369
-110,538
-60,779
-2,741
91,205
51,659
54,387
-17,901
-71,621
25,813
6,363
5,654
Depreciation
781
481
481
798
776
639
532
482
373
186
912
952
729
889
319
Amortisation
Tax
Stock
-1,101
1,457
-587
-134
-1,449
-1,595
5,134
571
668
-369
-74
-357
-2,480
-840
552
3,768
Debtors
-9,735
7,252
-13,070
-834
2,561
15,096
-17,571
14,197
108
-5,138
-3,137
-3,799
-20,714
36,070
-6,631
11,348
Creditors
-4,626
3,349
-2,345
-4,086
2,493
-20,589
11,984
1,448
-2,941
2,276
-18,163
15,903
2,501
-590
14,314
Accruals and Deferred Income
-3,165
-3,773
-30,891
-4,346
9,339
26,943
11,410
4,025
-33,067
35,765
395
117
-1,163
1,310
-8,507
11,719
Deferred Taxes & Provisions
-2,500
2,500
Cash flow from operations
84,919
-84,306
-24,334
65,888
-28,851
-116,909
-24,309
-11,504
54,903
95,580
37,516
5,687
-46,137
-7,968
19,138
2,576
Investing Activities
capital expenditure
-1,062
-399
-119
-980
-663
-498
-982
-746
-304
-1,550
-1,388
-639
Change in Investments
cash flow from investments
-1,062
-399
-119
-980
-663
-498
-982
-746
-304
-1,550
-1,388
-639
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue
202,733
-47,953
-1
55,559
interest
cash flow from financing
202,733
-47,953
-1
55,559
cash and cash equivalents
cash
69,177
-77,471
-21,355
51,777
-28,817
-116,198
-22,760
-11,222
238,809
37,535
25,461
5,751
-46,277
-15,992
16,199
56,014
overdraft
change in cash
69,177
-77,471
-21,355
51,777
-28,817
-116,198
-22,760
-11,222
238,809
37,535
25,461
5,751
-46,277
-15,992
16,199
56,014
kidney cancer care limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for kidney cancer care limited. Get real-time insights into kidney cancer care limited's credit score, group structure and payment trends.
Perform a competitor analysis for kidney cancer care limited by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other micro companies, companies in GU4 area or any other competitors across 12 key performance metrics.
kidney cancer care limited Ownership
KIDNEY CANCER CARE LIMITED group structure
Kidney Cancer Care Limited has no subsidiary companies.
Ultimate parent company
KIDNEY CANCER CARE LIMITED
05937304
KIDNEY CANCER CARE LIMITED Shareholders
The sole shareholder of Kidney Cancer Care Limited is -.
-
-
kidney cancer care limited directors
Kidney Cancer Care Limited currently has 9 directors.
The longest serving directors include
Mr Nicholas Cox (Oct 2012) and
Mr Berkeley Greenwood (Oct 2013).
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to kidney cancer care limited.
kidney cancer care limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for KIDNEY CANCER CARE LIMITED. This can take several minutes, an email will notify you when this has completed.
kidney cancer care limitedCompanies House Filings - See Documents
